Ocular melanoma cells with the activated MAPK pathway have been reported to be modestly sensitive to MAPK/ERK kinase (MEK) inhibitors with or without combination treatment with the protein kinase C (PKC) inhibitor [67]. Here, MAP2K7 is linked to melanoma.